Please login to the form below

Not currently logged in

Dragonfly signs Celgene as partner for NK cell platform

Dragonfly Therapeutics

Extends presence in haemato-oncology and solid tumours

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

The majority of patients on Tremfya achieved at least a 90% improvement from PASI score

Lilly partners with AC Immune on tau drug for Alzheimer’s

AC ImmunePotential payments of $1.7bn to Swiss firm

Axovant drops last ‘legacy’ drug to focus on gene therapies

Decision comes after nelotanserin failed to meet efficacy target

AZ and CRUK launch Cambridge genomics centre

New centre adds to Cambridge's biotech cluster

BMS to test Vedanta’s bacterial therapy with Opdivo

Will be trialled in those with advanced or metastatic cancers

UK’s genomics leadership attracts IQVIA investment, regardless of Brexit

IQVIAInvests in Genomics England alliance, plus clinical trials expansion

Biogen picks up another drug from wide-ranging Ionis alliance

BiogenAims to follow success of Spinraza

CAR-Ts take centre stage as ASH18 comes to a close

Candidates from Allogene, Legend Biotech and Novartis were among the highlights

clusterAdopting a creative IP approach towards biotech clusters

Why big pharma paradigm needs to change

Featured jobs

Subscribe to our email news alerts


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...